Follitropin delta: recombinant human follicle stimulating hormone (rhFSH) for multiple follicles stimulation in women undergoing assisted reproductive technologies (ART)

Abstract

Assisted reproductive technologies It is a process that allows infertility couples to have children. Data in the United States shows that approximately 1 in 5 women (19%) experience this problem. The process starts with stimulating the follicles in the ovaries to grow, then collecting oocytes and fertilizing with sperm outside the body. When it develops into an embryo, the embryo is placed in the uterus for implantation. remaining embryos can be frozen for future use. Follitropin delta is the first recombinant human follicle-stimulating hormone (rhFSH) produced from a human cell line. Used for stimulating follicles in the ovaries. From the efficacy study results, follitropin delta was administered at a fixed dose that was individualized according to anti-Mullerian hormone (AMH) ​​and body weight. The doctor cannot adjust the dosage. Compare Follitropin alfa or Follitropin beta is conventional dose that your doctor can adjust. Results showed that the ongoing pregnancy rate and number of oocytes retrieved recovered using In vitro fertilization (IVF)/Intracytoplasmic sperm injection (ICSI) technology of Follitropin delta were not inferior to Follitropin alfa and Follitropin beta. However, the incidence of ovarian hyperstimulation syndrome was found to be significantly lower. Therefore, the above comparison may indicate Individualized fixed dosing The efficiency is no different and more safety than using traditional medicine. Due to the Phase III study not covering all patient groups, such as polycystic ovarian syndrome (PCOS), etc., in the future, there is still a need to be further study of the dose administered.